BRAFTOVI + CETUXIMAB
BRAFTOVI + CETUXIMAB
BRAFTOVI is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.1
Presentation
BRAFTOVI (encorafenib) is a targeted therapy that demonstrates, in combination with cetuximab, a breakthrough in overall survival.1BEACON CRC, the only Phase 3 trial to exclusively study patients with BRAFV600E-mutant mCRC, demonstrates unprecedented OS and ORR results for these patients.3
Based on BEACON CRC data, the European Commission approved BRAFTOVI for patients with BRAFV600E-mutant mCRC, who have received prior systemic therapy.1
BRAFTOVI regimen provides an actionable reason to test all patients with mCRC for a BRAFV600E mutation at diagnosis.
Choose BRAFTOVI + cetuximab for your patients with BRAFV600E-mutant mCRC, who have received prior systemic therapy
BRAFTOVI + cetuximab significantly improved the median overall survival vs control arm1
BRAFTOVI + cetuximab demonstrated significantly higher response rates vs control arm1
Fewer patients receiving BRAFTOVI + cetuximab discontinued therapy due to AEs compared to control arm3
BRAFTOVI + cetuximab provide an actionable reason to test all patients with mCRC for BRAFV600E mutation at diagnosis1